US650760A - Gelatin capsule. - Google Patents

Gelatin capsule. Download PDF

Info

Publication number
US650760A
US650760A US73899399A US1899738993A US650760A US 650760 A US650760 A US 650760A US 73899399 A US73899399 A US 73899399A US 1899738993 A US1899738993 A US 1899738993A US 650760 A US650760 A US 650760A
Authority
US
United States
Prior art keywords
capsule
pepsin
gelatin
stomach
pill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US73899399A
Inventor
Frederick H Metcalf
Original Assignee
Frederick H Metcalf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frederick H Metcalf filed Critical Frederick H Metcalf
Priority to US73899399A priority Critical patent/US650760A/en
Priority claimed from US18307A external-priority patent/US671804A/en
Application granted granted Critical
Publication of US650760A publication Critical patent/US650760A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S206/00Special receptacle or package
    • Y10S206/819Material

Description

Patented May 29, I900.

F. H. METCALF.

GELAT-IN CAPSULE. (Applica tion filed Dec. 2, 1399.

(No Model.)

wwmm

5L4 JV M THE NORRXS PETERS CO, PNOYO-UTHO. WASHINGTON. n. C

Fries.

ranonmcx 1-1. METCALF, or FRANKLIN, ILLINOiS.

GELATIN CAPSU LE.

S PECIFICATION forming part of Letters Patent No. 650,760, dated May 29, 1900.

Application filed December 2, 18991 $erial No.'738;993. (No infidel.)

To all whom it may concern.-

Be it known that I FREDERICK H. CALF, a citizen of the United States, residing at Franklin, in the county of Morgan and State of Illinois, have invented new and useful Im provements in Capsules; of which the following is a specification.

This invention relates to improvements in gelatin capsules and gelatin-coated pills and tablets, and has especial reference to capsules, increasing their solubility when used in connection with compounds which they incase.

The object of the invention is to provide a capsule and coating for pills which will be more soluble and susceptible to digestion when taken into the stomach than the ordinary capsule or gelatin-coated pill or tablet, as is now marketed.

The invention consists of mixing in the gelatin composition while it is in a liquid state a' sufficient quantity of pepsin or other drug which will assist the stomach to digest the capsule-shell or coating of pill or tablet.

Many other objects and advantages will be hereinafter referred to, and particularly pointed out in the claim.

In the drawings forming a part of this specification, Figure 1 is a section of the capsule. Fig. 2 is a similar View showing the application of the invention to pills. Fig. 3 is a sectional view of a capsule, showing another mode of applying my invention. Fig. at is a sectional View of a further modification of a capsule.

In the drawings, 1 represents a capsule provided with a mixture of pepsin In Fig. 2 the invention is applied to a pill, the mode of operation and advantages obtained being substantially the same.

It is a well-known fact that frequently capsules are not easily digestible and under some circumstances tend to deter the quick and active operation of the medicine after it reaches the stomach. It is the purpose of this invention to assist the stomach in reducing the capsule-shell when it incases a compound or the coating of pill or tablet. The proportion of pepsin mixed with the capsule orcoating of pill or tablet when used for this purpose will be such as to not aifect the medicine contained within it, but to cowork with it. A

sufficient quantity is used to quickly and eliec= tually reduce the capsule-shell or coating of pill or tablet immediately after it is taken into the stomach, so as to expose the compound to the quick motion of the system to which and for which it was intended;

I propose to make a capsule especially pre} pared to contain compounds intended to aid digestion. For such purposes a greater quantity of pepsin will be added to the gelatin mixture than would otherwise be added when the capsules are to be used for ordinary purposes. In such cases the pepsin not only as sists the stomach to digest the capsule, but also acts in conjunction with the compound to accomplish its mission.

In the manufacture of gelatin capsules the mixture is first reduced by heat and water to a-liquid form and the composition thoroughly mixed. It is at this stage of the preparation of the composition that I put in a sufficient quantity of pepsin according to the intended purpose of the-capsule. In applying the improvement to pills the same principle is em ployed. The pill is prepared in the usual manner, after which it is rolled in a liquid composition of capsule-gelatin combined with pepsin, as before stated. I do not limit myself to the specific use of pepsin, as any analogous drug which can be mixed in with the composition without destroying or in any way affecting the gelatin can be substituted.

, It will be seen that the invention is extremely simple and of great value where it is of absolute necessity in many cases that the medicine within the capsule should reach the stomach and act immediately. By mixing the pepsin in the composition as above described I have not only produced a novel means of assisting nature, but have provided something which can be produced cheaply and at the same time have not added any thing to the weight of the capsule-shell, nor have I mixed a drug with the gelatin which will in any way destroy any element of the composition.

In many cases the capsule-shell can be used to assist digestion a suflicient quantity of the pepsin having been mixed with the gelatin in its manufacture.

As shown in Fig. 3 the walls of the capsule are made double and a layer of pepsin is interposed, and in Fig. 41- the construction is substantially the same, except that a small opening, 4 is provided in the outer capsule, so as to permit the juices in the stomach to immediately coact with the pepsin between the Walls.

' Having thus described my invention, What I claim is- As an article of man u facture, a gelatin capsule having pepsin incorporated with its 00111' to position, as set forth.

In testimony whereof I have hereunto set my hand in the presence of two subscribing witnesses.

FREDERICK H. MEICALF.

\Vitnesses:

OHAs. A. BARNES, LENA C. ENGEL.

US73899399A 1899-12-02 1899-12-02 Gelatin capsule. Expired - Lifetime US650760A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US73899399A US650760A (en) 1899-12-02 1899-12-02 Gelatin capsule.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73899399A US650760A (en) 1899-12-02 1899-12-02 Gelatin capsule.
US18307A US671804A (en) 1899-12-02 1900-05-28 Coated pill, &c.

Publications (1)

Publication Number Publication Date
US650760A true US650760A (en) 1900-05-29

Family

ID=2719330

Family Applications (1)

Application Number Title Priority Date Filing Date
US73899399A Expired - Lifetime US650760A (en) 1899-12-02 1899-12-02 Gelatin capsule.

Country Status (1)

Country Link
US (1) US650760A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
US3285408A (en) * 1964-10-16 1966-11-15 Lilly Co Eli Capsule with integral locking band
US3403106A (en) * 1965-07-12 1968-09-24 Armour & Co Buoyant soap cake and preparation thereof
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
US3639259A (en) * 1969-04-09 1972-02-01 Ncr Co Enzymatic treatment of gelled proteinaceous film material
US3943238A (en) * 1972-11-01 1976-03-09 Meija Seika Co., Ltd. Method for the preparation of medicinal capsules
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
US4261969A (en) * 1979-05-03 1981-04-14 World Health Organization Controlled drug release composition
US4609403A (en) * 1984-03-12 1986-09-02 Warner-Lambert Company Foam soft gelatin capsules and their method of manufacture
US5750145A (en) * 1995-07-28 1998-05-12 Bristol-Myers Squibb Company Stable gelatin coated aspirin tablets

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
US3285408A (en) * 1964-10-16 1966-11-15 Lilly Co Eli Capsule with integral locking band
US3403106A (en) * 1965-07-12 1968-09-24 Armour & Co Buoyant soap cake and preparation thereof
US3639259A (en) * 1969-04-09 1972-02-01 Ncr Co Enzymatic treatment of gelled proteinaceous film material
US3943238A (en) * 1972-11-01 1976-03-09 Meija Seika Co., Ltd. Method for the preparation of medicinal capsules
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
US4261969A (en) * 1979-05-03 1981-04-14 World Health Organization Controlled drug release composition
US4609403A (en) * 1984-03-12 1986-09-02 Warner-Lambert Company Foam soft gelatin capsules and their method of manufacture
US5750145A (en) * 1995-07-28 1998-05-12 Bristol-Myers Squibb Company Stable gelatin coated aspirin tablets

Similar Documents

Publication Publication Date Title
FitzGerald Coxibs and cardiovascular disease
US5009894A (en) Arrangement for and method of administering a pharmaceutical preparation
Brand et al. Drugs used in motion sickness. A critical review of the methods available for the study of drugs of potential value in its treatment and of the information which has been derived by these methods.
US20070045134A1 (en) Aqueous Solution of an Analgesic and a Dispenser Therefor
Ikeda et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study
Nurmi-Lüthje et al. Post-Fracture Prescribed Calcium and Vitamin D Supplements Alone or, in Females, with Concomitant Anti-Osteoporotic Drugs is Associated with Lower Mortality in Elderly Hip Fracture Patients
Deutsch et al. Postoperative hyponatremia with the inappropriate release of antidiuretic hormone
EP2117506A2 (en) Methods of making pharmaceutical components for customized drug products
Launay‐Vacher et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients
Philpott et al. Republished: drug-induced gastrointestinal disorders
US20120261275A1 (en) Child resistant package with floating panel
Risser et al. NSAID prescribing precautions
Shin et al. A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina
Freston Cimetidine in the treatment of gastric ulcer: review and commentary
Lamy Renal effects of nonsteroidal antiinflammatory drugs: heightened risk to the elderly?
Huberty et al. Endoscopic gastric reduction with an endoluminal suturing device: a multicenter prospective trial with 1-year follow-up
Teixeira Rebound effect of drugs: fatal risk of conventional treatment and pharmacological basis of homeopathic treatment.
Makrides Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy
Nulton-Persson et al. Inhibition of cardiac mitochondrial respiration by salicylic acid and acetylsalicylate
Maron et al. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial)
US20170087090A1 (en) Portable powder delivery system and method
Misra et al. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial
PLUMLEE et al. Myocardial infarction during and following anesthesia and operation
Knutsson On limy bile
US20050088632A1 (en) Vitasolve dissolving film strips with supplements pharmaceutical drug(RX), +vitamins